Semax-Selank is a vendor blend of two Russian-developed peptides, Semax and Selank, sold together in one vial; no published trial has tested the combination.
Each ingredient has its own hub: Semax and Selank. Both are seven-amino-acid peptides from Moscow research institutes, and both end in the same Pro-Gly-Pro tail. Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is built on a fragment of the hormone ACTH. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is built on tuftsin, a small immune peptide, according to a 2026 review in JAAOS Global Research & Reviews. A 2001 study in Bioorganicheskaya Khimiya found that both inhibit enzymes in human serum that break down enkephalins.
Semax-Selank has no FDA approval, and as of October 2026 no PubMed or ClinicalTrials.gov record tests the two peptides given together.
Separately, each has a Russian clinical record. The 2026 JAAOS review states that Selank is approved in Russia for anxiety, and a 2014 Russian study compared it with the benzodiazepine phenazepam in 60 patients. Semax has been used in Russia for ischemic stroke, including a 2018 study of 110 stroke patients. The closest thing to a combination study is a 2020 brain-imaging study of 52 healthy volunteers that gave Semax, Selank or placebo to separate groups. Neither peptide appears in the FDA’s Drugs@FDA database.
A blend is harder to verify than a single peptide. The label makes two claims, so a lab has to confirm two identities and two amounts. Belgian regulators at Sciensano identified Selank and Semax in suspicious seized preparations in 2017 and 2018, then developed an LC-MS/MS screening method because these peptides were freely sold online as injectable powder and nasal sprays.
Before trusting a Semax-Selank label, check that batch’s published result on our latest tests page or in Janoshik’s public results database. Our index has no published results for Semax-Selank yet. When the first published result arrives, a vendor leaderboard appears above.